MedTrace Logo

A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers

NCT00000879 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2021-10-29

No results posted yet for this study

Summary

The purpose of this study is to see if giving the ALVAC vCP1452 anti-HIV vaccine alone or with another vaccine called AIDSVAX B/B to babies of HIV-positive mothers is safe. The study will also look at how these vaccines affect a baby's immune system. Most HIV-positive children get HIV from their mothers during pregnancy or birth. Treatment with anti-HIV drugs can reduce the baby's risk of getting HIV. Vaccines also may help prevent HIV infection. This study will look at whether the ALVAC vCP1452 vaccine and the AIDSVAX B/B vaccine can help the body fight off HIV infection. There is no chance of getting HIV infection from the vaccines. (This study has been changed. In earlier versions, ALVAC vCP205 and AIDSVAX B/E were going to be used.)

Conditions

  • HIV Infections
  • HIV Seronegativity

Interventions

BIOLOGICAL

ALVAC(2)120(B,MN)GNP (vCP1452)

BIOLOGICAL

MN rgp120/HIV-1 and GNE8 rgp120/HIV-1

BIOLOGICAL

ALVAC-HIV MN120TMG (vCP205)

Sponsors & Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    collaborator NIH

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • John Lambert

  • Daniel Johnson

  • Stuart Starr

Study Design

Purpose
PREVENTION
Masking
DOUBLE

Eligibility

Min Age
0 Days
Max Age
3 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Completion
2005-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000879 on ClinicalTrials.gov